The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
Abstract
Phase 2a proof-of-concept trial in IPF that reported acceptable safety and between-group differences favoring taladegib on percent predicted FVC, HRCT total lung capacity, and quantitative interstitial lung disease measures over 12 weeks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationThe mechanisms of Hedgehog signalling and its roles in development and disease
Briscoe, J., & Thérond, P. P. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3598 · Cited by 1,751
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00026-2015 · Cited by 468
Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis
Sakai, & Tager, A. M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.001 · Cited by 285
Finnerty, J. P., Ponnuswamy, A., Dutta, P., Abdelaziz, A., & Kamil, H. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01783-1 · Cited by 209
Lacouture, M. E., Dréno, B., Ascierto, P. A., Dummer, R., Basset-Seguin, N., Fife, K., Ernst, S., Licitra, L., Neves, R. I., Peris, K., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0186 · Cited by 165
Role of Sonic Hedgehog in idiopathic pulmonary fibrosis
Bolaños, A. L., Milla, C. M., Lira, J. C., Ramírez, R., Checa, M., Barrera, L., García-Alvarez, J., Carbajal, V., Becerril, C., Gaxiola, M., et al. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00184.2012 · Cited by 160
Cigna, N., Moshai, E. F., Brayer, S., Marchal-Sommé, J., Wémeau-Stervinou, L., Fabre, A., Mal, H., Lesèche, G., Dehoux, M., Soler, P., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.08.019 · Cited by 148
Kim, H. J., Brown, M. S., Elashoff, R. M., Li, G., Gjertson, D. W., Lynch, D. A., Strollo, D. C., Kleerup, E. C., Chong, D. Y., Shah, S. K., et al. (2011) · European Radiology · doi:10.1007/s00330-011-2223-2 · Cited by 125
Self-citation
Cited by
Emerging Therapies in Pulmonary Fibrosis
Etchingham-Coll, H., Temizel, E., Okezie-Enyioma, N., Martin, N., Kaenmuang, P., Coghlan, S., Spagnolo, P., & Chaudhuri, N. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00349-y · Cited by 6
“In ENV‑IPF‑101 (NCT04968574) [73], a phase 2a proof‑of‑con‑ cept trial, 41 patients with untreated IPF were randomised to taladegib 200 mg once daily or placebo for 12 weeks.”
Hedgehog signalling: on the way to curing idiopathic pulmonary fibrosis
Spagnolo, P., & Khor, Y. H. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00284-x
Mansour, G. K., Hajjar, A. W., & Sukkarieh, H. H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1748453 · Cited by 1
Advances in pharmacotherapy for fibrotic interstitial lung disease
Feng, X., Deng, M., Miao, J., Zheng, Z., & Hou, G. (2026) · Medical Review · doi:10.1515/mr-2025-0086
Novara, M. E., Chirulli, M., Vitulo, P., Carollo, A., & Provenzani, A. (2026) · Biomedicines · doi:10.3390/biomedicines14061293 · Cited by 1
“By blocking SMO, it reduces fibroblast activation and myofibroblast differentiation, thereby limiting extracellular matrix deposition and the progression of fibrosis in IPF [86].”
Metadata
- Authors
- Maher, T. M., Goldin, J. G., Hood, J., Pitman, J., de los Rios, M., Hobbs, B. P., Yu-Lin, A. B., Buendia-Roldan, I., Thien, F., Song, J. W., Perea, P. C., Ramírez-Rivera, A., & DiFrancesco, A.
- Affiliations
- University of Southern California (US)
- University of California, Los Angeles (US)
- National University of Malaysia (MY)
- Box Hill Hospital (AU)
- Asan Medical Center (KR)
- Intarcia Therapeutics (United States) (US)
- Corresponding author
- DiFrancesco, A
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2025-11
- Volume
- 13
- Issue
- 11
- Pages
- 1001-1010
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W4414708803
- Cited by
- 9
- References
- 31
- Citations by year
- 2026: 8 · 2025: 1
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Respiratory Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- idiopathic pulmonary fibrosis, Hedgehog signaling, Hedgehog pathway inhibitors, antifibrotic therapy, forced vital capacity, dysgeusia, drug safety, interstitial lung disease
- MeSH terms
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Pyridines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. https://app.cochat.ai/papers/10.1016/s2213-2600(25)00239-5
- The paper
- Maher, T. M., Goldin, J. G., Hood, J., Pitman, J., de los Rios, M., Hobbs, B. P., Yu-Lin, A. B., Buendia-Roldan, I., Thien, F., Song, J. W., Perea, P. C., Ramírez-Rivera, A., & DiFrancesco, A. (2025). Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(25)00239-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.